Literature DB >> 12410057

Beneficial effects of botulinum toxin type a for patients with painful tic convulsif.

Federico Micheli1, María Clara Scorticati, Gabriela Raina.   

Abstract

Botulinum toxin is a well-known therapy for patients with diverse movement disorders. Its application has been extended to other disorders. Here, we document the case of a 70-year-old man with hemifacial spasm associated to trigeminal neuralgia secondary to an ectatic basilar artery. He was treated with botulinum toxin type A, 2.5 mouse units over five sites at the orbicularis oculi and one over the buccinator muscle. After botulinum toxin injections, relief was gained not only from twitching but also from pain. When the effects of the toxin vanished, spasms and pain recurred. Further infiltrations were given every 12 weeks following the same response pattern. This observation further validates the increasing role of botulinum toxin in pain management.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12410057     DOI: 10.1097/00002826-200209000-00006

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  15 in total

1.  Chronic eye movement induced pain and a possible role for its treatment with botulinum toxin.

Authors:  B J L Burton; S R Khan; J P Lee
Journal:  Br J Ophthalmol       Date:  2003-09       Impact factor: 4.638

2.  A new target for the treatment of trigeminal neuralgia with botulinum toxin type A.

Authors:  Chuanjie Wu; Nanchang Xie; Hongbo Liu; Haifeng Zhang; Lu Zhang; Yajun Lian
Journal:  Neurol Sci       Date:  2017-10-30       Impact factor: 3.307

3.  New treatments for tic disorders.

Authors:  Mohammad M Qasaymeh; Jonathan W Mink
Journal:  Curr Treat Options Neurol       Date:  2006-11       Impact factor: 3.972

4.  Safety and efficacy of botox injection in alleviating post-operative pain and improving quality of life in lower extremity limb lengthening and deformity correction.

Authors:  Reggie C Hamdy; Kathleen Montpetit; Joanne Ruck-Gibis; Kelly Thorstad; Ellen Raney; Michael Aiona; Robert Platt; Allen Finley; William Mackenzie; James McCarthy; Unni Narayanan
Journal:  Trials       Date:  2007-09-28       Impact factor: 2.279

5.  Therapeutic effect of Botulinum toxin-A in 88 patients with trigeminal neuralgia with 14-month follow-up.

Authors:  Shuang Li; Ya-Jun Lian; Yuan Chen; Hai-Feng Zhang; Yun-Qing Ma; Cai-Hong He; Chuan-Jie Wu; Nan-Chang Xie; Ya-Ke Zheng; Yi Zhang
Journal:  J Headache Pain       Date:  2014-06-22       Impact factor: 7.277

6.  Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial.

Authors:  Haifeng Zhang; Yajun Lian; Yunqing Ma; Yuan Chen; Caihong He; Nanchang Xie; Chuanjie Wu
Journal:  J Headache Pain       Date:  2014-09-27       Impact factor: 7.277

7.  Single-dose botulinum toxin type a compared with repeated-dose for treatment of trigeminal neuralgia: a pilot study.

Authors:  Haifeng Zhang; Yajun Lian; Nanchang Xie; Chen Chen; Yake Zheng
Journal:  J Headache Pain       Date:  2017-08-10       Impact factor: 7.277

8.  Efficacy and Safety of Botulinum Toxin Type A in Treating Patients of Advanced Age with Idiopathic Trigeminal Neuralgia.

Authors:  Jing Liu; Ying-Ying Xu; Qi-Lin Zhang; Wei-Feng Luo
Journal:  Pain Res Manag       Date:  2018-04-05       Impact factor: 3.037

Review 9.  Therapeutic efficacy and safety of botulinum toxin type A in trigeminal neuralgia: a systematic review.

Authors:  Yong Hu; Xiaofei Guan; Lin Fan; Mu Li; Yiteng Liao; Zhiyu Nie; Lingjing Jin
Journal:  J Headache Pain       Date:  2013-08-21       Impact factor: 7.277

Review 10.  Therapeutic efficacy and safety of Botulinum Toxin A Therapy in Trigeminal Neuralgia: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Mostafa Ebraheem Morra; Ahmed Elgebaly; Ahmed Elmaraezy; Adham M Khalil; Ahmed M A Altibi; Tran Le-Huy Vu; Mostafa Reda Mostafa; Nguyen Tien Huy; Kenji Hirayama
Journal:  J Headache Pain       Date:  2016-07-05       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.